Scientists develop a dual action strategy to destabilize the COVID virus

An unprecedented study led by researchers at the University of Malaga proposes a new antiviral strategy against SARS-CoV-2 -the virus responsible for causing COVID-19 disease- based on a treatment that combines two complementary approaches, capable of attacking the virus simultaneously, forcing its instability and hindering its ability to adapt.

The results of this work, published in the journal Antimicrobial Agents and Chemotherapy, and part of Sergio Ortega del Campo's Doctoral Thesis, recently defended within the Molecular and Cellular Biology Doctoral Program of the UMA, pave the way for the development of more effective therapies against emerging viruses, as well as combating new, more resistant variants of coronavirus.

Dual action

Professor at the Department of Cell Biology, Genetics and Physiology Ana Grande, one of the main authors of this research, explains that, on the one hand, they designed small peptides -protein fragments- capable of blocking key viral proteins involved in the replication of its genetic material and the immune evasion and, on the other hand, they used a compound (5-fluorouracil) that introduces errors during viral genome replication.

According to Grande, this study also demonstrates that this combined treatment not only reduces the viral load but also strongly alters its genetic diversity, "destabilizing the viral population and facilitating its extinction". This dual action causes, therefore, a synergistic effect: the virus not only replicates less efficiently but also accumulates mutations to the point of non-viability of the virus.

"Moreover, since the viral proteins targeted by peptides are highly conserved among different coronaviruses, this strategy could have wider applications in the development of broad-spectrum antivirals," she says.

Multidisciplinary work: from computational design to experimental validation

'Synergistic antiviral effects of structure-guided peptides and a mutagenic base analog on SARS-CoV-2 replication' is the result of a multidisciplinary work in which, together with the UMA, researchers from IBIMA Platforma BIONAND, Hospital Universitario Virgen de la Victoria of Malaga, IDIBE-Universidad Miguel Hernández, from the Severo Ochoa Molecular Biology Center (CSIC-UAM), Universidad Autónoma de Madrid and Fundación Jiménez Díaz have all participated, allowing the problem to be approached from different perspectives, from computational design to experimental validation.

Although this is a laboratory study, specifically conducted in cell cultures, its developers, who continue to pursue this line of R&D, have applied for a patent to protect this therapeutic approach, with the aim of facilitating its possible transfer and future development.

Source:

University of Malaga

Journal reference: